CCDC6

Across TCGA pan-cancer cohorts, CCDC6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC6 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCDC6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CCDC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.893	0.633	.002	20	view →
LUAD	DFS	Median	II,III,IV	0.209	0.849	<.001	19	view →
HNSC	DFS	Tertile	II,III,IV	0.986	0.869	.017	8	view →
UCEC	DFS	Quartile	All	0.734	0.939	.016	6	view →
CCRCC	DFS	Tertile	All	0.659	0.838	.041	3	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC6–PDAC (DFS)

Open the PDAC breakdown →